Back
Top 0.8%
18.1%
#1
18.1%
Top 65%
8.0%
Top 0.6%
6.6%
Top 23%
5.1%
Top 0.2%
5.1%
Top 11%
3.9%
Top 1%
3.9%
Top 1%
3.9%
Top 77%
2.2%
Top 48%
2.0%
Top 9%
2.0%
Top 7%
1.4%
Top 5%
1.4%
Top 2%
0.7%
Top 13%
0.7%
Top 6%
0.7%
Top 7%
0.5%
Keynote 48: Is it really for everyone?
2020-04-24
oncology
Title + abstract only
View on medRxiv
Show abstract
Burtness et al. recently published the landmark Keynote-48 study, demonstrating a survival benefit for pembrolizumab monotherapy and pembrolizumab/chemotherapy, compared with cetuximab/chemotherapy, in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). These data are impactful and practice-changing, and have rapidly been adopted in practice, with increasing numbers of HNSCC patients receiving either pembrolizumab monotherapy, or pembrolizumab / chemotherapy, in the...
Predicted journal destinations
1
Cancers
57 training papers
2
Frontiers in Oncology
34 training papers
3
PLOS ONE
1737 training papers
4
Clinical Cancer Research
22 training papers
5
Nature Communications
483 training papers
6
BMC Cancer
21 training papers
7
eLife
262 training papers
8
Cancer Medicine
17 training papers
9
British Journal of Cancer
22 training papers
10
Scientific Reports
701 training papers
11
BMJ Open
553 training papers
12
JAMA Network Open
125 training papers
13
Nature Medicine
88 training papers
14
Heliyon
57 training papers
15
International Journal of Cancer
18 training papers
16
Frontiers in Immunology
140 training papers
17
Diagnostics
36 training papers
18
Journal of Clinical Investigation
50 training papers